A portfolio spanning the disease continuum

Active study portfolio

Currently open studies

• A Phase I/II Trial of Concurrent Chemohormonal Therapy Using Enzalutamide (MDV-3100) and Cabazitaxel in Patients with Metastatic Castration Resistant Prostate Cancer

  Phase I/II
  NCT02522715

• ARN-509 + Abiraterone acetate + Leuprolide with Stereotactic, Ultra-Hypofractionated Radiation (AASUR) in Very High-Risk Prostate Cancer: A Single Arm, Phase II Study

  Phase II
  NCT02772588

• A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients with Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects

  Phase II
  NCT03012321

• IRONMAN: International Registry for Men with Advanced Prostate Cancer
  NCT03151629

• PRODIGY: Observational study to describe effectiveness of olaparib in subjects with metastatic castration-resistant prostate cancer who have failed prior treatment with a new hormonal agent and carry selected homologous recombination repair gene mutations

  IRONMAN Registry Substudy
  Substudy

• EMPRO: Engaging Men in Patient Reported Outcomes

  IRONMAN Registry Substudy
  Substudy

• CUETIP: Clinical Utility of an AI-Enabled PSMA-Targeted Imaging Biomarker in Prostate Cancer

  IRONMAN Registry Substudy
  Substudy

• BIOGUARD: BIOmarker landscape in GU cancers: Assessment in the Real-worlD

  IRONMAN Registry Substudy
  Substudy

• IRONSeq: Characterizing the whole genome landscape of the IRONMAN Registry

  IRONMAN Registry Substudy
  Substudy

• Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer

  Phase III
  NCT03574571

• Metacure: Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma
  NCT03436654

• A Phase II Study of Carboplatin, Cabazitaxel and Abiraterone in High Volume Metastatic Castration Sensitive Prostate Cancer (CASCARA)

  Phase II
  NCT03934840

• A Single-arm, Phase 2 Study to Evaluate the Safety and Efficacy of IMMU-132 in Patients with Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone

  Phase 2
  NCT03725761

• A Phase Ib/II Study of Intermittent Talazoparib Plus Temozolomide in Subjects with Metastatic Castration Resistant Prostate Cancer and No Mutations in DNA Damage Repair

  Phase Ib/II
  NCT04019327

• An open-label Phase I/IIa study to evaluate the safety and efficacy of CCS1477 as monotherapy and in combination in patients with advanced solid/metastatic tumours

  Phase I/IIa
  NCT03568656

• Single Arm Phase II Study of Abiraterone + Atezolizumab + Lupron and Stereotactic Body Radiotherapy (SBRT) to the Prostate in Men with Newly Diagnosed Hormone-sensitive Metastatic Prostate Cancer

  Phase II
  NCT04262154

• A Phase 2 Multicohort Study of Nivolumab in Combination with Docetaxel and Androgen Deprivation Therapy in Metastatic Hormone Sensitive Prostate Cancer Patients with DNA Damage Repair Defects or Inflamed Tumors

  Phase 2
  NCT04126070

• PROMISE: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness
  NCT04995198

• An open-label Phase I/IIa study to evaluate the safety and efficacy of CCS1477 as monotherapy in patients with advanced haematological malignancies

  Phase I/IIa
  NCT04068597

• DASL-HiCaP: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (ANZUP1801). A randomised phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high risk, clinically localised prostate cancer

  phase 3
  NCT04136353

• Neoadjuvant darolutamide and abemaciclib in high-risk prostate cancer
  NCT05617885

• A Phase 1b/2 Study Evaluating the Activity of Tinengotinib (TT–00420) in Combination with Androgen Receptor Signaling Inhibitors (ARSIs) in Patients with Metastatic Castration Resistant Prostate Cancer

  Phase 1b/2
  NCT06457919

• TALazoparib with or without ENzaluTamide in patients with metastatic castration-resistant prostate cancer and HRR mutations after progression on abiraterone acetate (TALENT)
  NCT06844383

• A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1311 in Subjects with Advanced/Metastatic Solid Tumors

  Phase 1/2a
  NCT05914116

• A Phase 1b/2a, Multicenter, Open-Label Study of Pocenbrodib as Monotherapy and in combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617 in Participants with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

  Phase 1b/2a
  NCT06785636

• Phase 1, Dose-Escalation Study of KTX2001 (an NSD2 Inhibitor) Alone and in Combination With Darolutamide for Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)

  Phase 1
  NCT07103018